Levoketoconazole

Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its commercial portfolio and development pipeline at three scientific meetings this fall: Breakthrough T1D Clinical & Research Congress (CRC), the 21st Annual Cardiometabolic Health Congress (CMHC), and the American Thyroid Association (ATA) Annual Meeting. “These presentations reflect the breadth and depth of our scientific work and collaborations across endocrinology, as well as our commitment to advancing care at every stage, from established therapies to emerging treatment approaches,” said Anh Nguyen, MD, Chief Medical Officer of Xeris Biopharma. “By sharing real-world experience with Recorlev and new research on Gvoke, we continue to build the evidence supporting therapies patients rely on today. At the same time, our TriNetX analysis expands our understanding of real-world biochemical control among patients with hypothyroidism treated with oral levothyroxine.” Presentation Highlights Severe Hypoglycemia – Gvoke at the 2026 Breakthrough T1D Clinical & Research Congress New real-world data examines the gap between HCP awareness of American Diabetes Association standard of care treatment guidelines for prescribing ready-to-use glucagon, when compared to actual prescribing practices. Data underscores the unmet clinical unmet need and ongoing opportunity to increase adoption of ready-to-use glucagon products. Hypercortisolism in Cushing’s Syndrome and associated cardiometabolic comorbidities – Recorlev at the 2026 Cardiometabolic Health Congress A compelling case study demonstrates normalization of cortisol following treatment with levoketoconazole, accompanied by meaningful improvements in multiple cardiometabolic parameters, in a patient with uncontrolled Type 2 diabetes, hypertension, and multiple comorbidities. This case study highlights the important role of cortisol normalization in cardiometabolic health. Hypothyroidism – Characterization of a real-world hypothyroid population using linked levothyroxine treatment and TSH data at the 2026 American Thyroid Association Annual Meeting First public presentation of a real-world analysis using linked levothyroxine treatment records and TSH laboratory data to characterize patients with hypothyroidism and explore approaches for longitudinal assessment. Presentation Details Breakthrough T1D Clinical & Research Congress (CRC 2026): October 9–10, 2026, Philadelphia, PA Abstract title : Ensuring Readiness: A Case For Proactive Glucagon Prescribing For Patients At Increased Risk of Severe Hypoglycemia Presenter : Natasha Ferguson, PhD (Xeris Biopharma) Presentation : Friday, October 9, 2026 (already presented) Annual Cardiometabolic Health Congress (CMHC 2026): October 15–16, 2026, Boston, MA Abstract title : Discontinuation of Antihypertensives and Insulin in a Patient with Difficult-to-Control Type 2 Diabetes and Hypertension After Treatment With Levoketoconazole Presenter : Lee Wesler, MD, FACP (Day Kimball Medical Group) Presentation : Thursday, October 15, 2026, 10:45 a.m. EST, and Friday, October 16, 2026, 6:15 p.m. EST American Thyroid Association (ATA 2026) Annual Meeting: November 4–7, 2026, Philadelphia, PA Abstract title : Characterization of a Real-World Hypothyroid Population Using Linked Levothyroxine Treatment and TSH Data: A TriNetX Analysis Presenter : James M. Meyer, PharmD, MBA (Xeris Biopharma) Presentation : Friday, November 6, 2026, 10:00 a.m. EST ABOUT RECORLEV ® Indication RECORLEV (levoketoconazole) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of use: RECORLEV is not approved for the treatment of fungal infections. Important Safety Information WARNING: HEPATOTOXICITY AND QT PROLONGATION Cases of hepatotoxicity with fatal outcome or requiring liver transplantation have been reported with oral ketoconazole. Some patients had no obvious risk factors for liver disease. RECORLEV is associated with serious hepatotoxicity. Evaluate liver enzymes prior to and during treatment. RECORLEV is associated with dose-related QT interval prolongation. QT interval prolongation may result in life-threatening ventricular dysrhythmias such as torsades de pointes. Perform ECG and correct hypokalemia and hypomagnesemia prior to and during treatment. RECORLEV is contraindicated in patients: With cirrhosis, acute liver disease or poorly controlled chronic liver disease, baseline AST or ALT >3 times the upper limit of normal, recurrent symptomatic cholelithiasis, a prior history of drug-induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease Taking drugs that cause QT prolongation associated with ventricular arrhythmias, including torsades de pointes With prolonged QTcF interval >470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome With hypersensitivity to levoketoconazole, ketoconazole, or any excipient in RECORLEV Taking certain drugs that are sensitive substrates of CYP3A4 or CYP3A4 and P-gp RECORLEV may lead to hypocortisolism with a potential for life-threatening adrenal insufficiency. Dosage reduction or interruption may be necessary Hypersensitivity to RECORLEV has been reported. Anaphylaxis has been reported with oral ketoconazole RECORLEV may lower serum testosterone in men and women. Inform patients to report associated symptoms Most common adverse reactions are nausea/vomiting, hypokalemia, hemorrhage/contusion, systemic hypertension, headache, hepatic injury, abnormal uterine bleeding, erythema, fatigue, abdominal pain/dyspepsia, arthritis, upper respiratory infection, myalgia, arrhythmia, back pain, insomnia/sleep disturbances, and peripheral edema Avoid use of strong CYP3A4 inhibitors and inducers 2 weeks before and during RECORLEV treatment. Consult approved product labeling for drugs that are substrates of CYP3A4, P-gp, OCT2, and MATE prior to initiating RECORLEV. For atorvastatin, metformin, and gastric acid modulators, see full Prescribing Information for recommendations regarding concomitant use with RECORLEV Breastfeeding is not recommended during treatment and for one day after final dose Please see full Prescribing Information , including Boxed Warning, for RECORLEV. ABOUT GVOKE ® Indication GVOKE (glucagon) is an antihypoglycemic agent indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years and older with diabetes. Important Safety Information GVOKE is contraindicated in patients with: Pheochromocytoma because of the risk of substantial increase in blood pressure Insulinoma because of the risk of hypoglycemia Prior hypersensitivity reaction to glucagon or to any of the excipients. Serious hypersensitivity reactions have been reported with glucagon, including generalized rash, and anaphylactic shock with breathing difficulties and hypotension GVOKE may stimulate the release of catecholamines from the tumor. If patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate intravenously has been shown to be effective in lowering blood pressure In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, administration may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously Patients with insufficient hepatic stores of glycogen may not respond to GVOKE for treatment of severe hypoglycemia. Insufficient hepatic stores of glycogen may be present in conditions such as states of starvation, or in patients with adrenal insufficiency or chronic hypoglycemia A skin rash called necrolytic migratory erythema (NME), has been reported post-marketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. GVOKE is not approved for continuous infusion. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks Most common adverse reactions reported in adult patients were nausea, vomiting, injection site edema raised 1 mm or greater, and headache Most common adverse reactions reported in pediatric patients were nausea, hypoglycemia, vomiting, headache, abdominal pain, hyperglycemia, injection site discomfort and reaction, and urticaria Patients taking concomitant beta-blockers may have a transient increase in pulse and blood pressure. In patients taking concomitant indomethacin, GVOKE may lose its ability to raise glucose or may produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin Please see full Prescribing Information for GVOKE. About Xeris Biopharma Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev ® , a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; Gvoke ® , a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis ® , a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol ® and XeriJect ® , for Xeris and its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, please visit us at xerispharma.com and follow on X , LinkedIn , or Instagram . Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for the Company, including statements, among other things, the market and therapeutic and commercial potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline the Company's plans regarding clinical developments, and other statements containing the words "achieve," "anticipate," “believe,” “continue,” “expect,” “potential,” “should,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors, and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements , include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, political unrest, trade disputes, changes in U.S. governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ U.S. Securities and Exchange Commission filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. US-GVK-26-00109 (v1) 10/26 Contacts Investor & Media Contact Cristi Barnett Vice President, Investor Relations ir@xerispharma.com

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放 截至10月14日15点59分，近期共有 517 本期刊发布了 957 篇文章，其中高血压相关的文章共 51 篇，覆盖 4 个领域的内容。中国专家参与发表的文章有 14 篇。今日，影响因子最高的文章刊登在 The Lancet Healthy Longevity (IF: 14.600) 期刊上。 今日头条 Headlines 01 J Psychosom Res IF: 03.300 焦虑和抑郁症状与未治疗慢性血栓栓塞性肺动脉高压患者心肺运动表现的横断面独立关联 Xinxin Wang, Fuhua Qiu, Sailan Li, Shumei Li, Hanbin Luo, Tiantian Zhou, etc. 慢性血栓栓塞性肺动脉高压（CTEPH）常伴随焦虑和抑郁症状，但这些症状与未治疗患者客观测量的心肺功能之间的关联尚不明确。这项横断面研究旨在探讨新诊断、未治疗的CTEPH患者中，焦虑和抑郁症状与心肺运动试验（CPET）变量的独立关联。 研究共纳入236例新诊断、未治疗的CTEPH患者。分别使用焦虑自评量表（SAS）和抑郁自评量表（SDS）评估焦虑和抑郁症状。所有患者均接受CPET、6分钟步行试验（6MWT）和右心导管检查。采用多变量线性回归模型调整关键临床混杂因素。 结果显示，经过调整后，较高的SAS和SDS评分与较低的运动能力和较差的通气效率独立相关。抑郁症状评分显示出更广泛的关联，与较低的峰值摄氧量（VO₂peak）、较低的厌氧阈值摄氧量、较短的6分钟步行距离（6MWD）和较低的氧脉搏独立相关（所有P < 0.05）。呼吸交换率（RER）与任一量表均无显著关联。 在未治疗的CTEPH患者中，较高的焦虑和抑郁症状评分与较低的运动能力和较差的通气效率独立相关，其中抑郁症状的关联更为广泛。这些发现支持在初始临床评估中更加关注心理症状。未来研究应探讨心理症状与功能恢复之间的双向关系。 本文由 天纳乾坤 编辑 扫描二维码查看源文 J Psychosom Res | Volume 211, Issue 10.1016/j.jpsychores.2026.112993 02 Am J Prev Cardiol IF: 05.900 抗高血压药物对痴呆、心脏病或死亡的感知价值：一项随机实验 Alexander Chaitoff, Ciaran Kohli-Lynch, Kenzie A Cameron, Donovan T. Maust, Kenneth M Langa, Deborah A Levine, etc. 许多符合条件的患者选择不使用抗高血压药物。目前尚不清楚，强调特定疾病的益处是否能激发更强的用药意愿，从而提供一种低成本的增加药物使用的方法。研究人员假设，将抗高血压药物的益处框定为预防特定病理（如痴呆），会影响患者对药物的估值。 为此，研究团队开展了一项随机、基于网络的实验，参与者为来自美国、年龄≥50岁且与人口普查匹配的成年人，通过CloudResearch Prime Panels招募。参与者按1:1:1:1随机分配到四种框架情景之一，描述临床医生建议开始抗高血压治疗，分别强调预防（1）痴呆、（2）心血管疾病（CVD）、（3）死亡，或（4）三者组合。主要结局是自报的每月自付支付意愿（WTP）。次要结局包括WTP占收入的比例、总感知价值、与临床医生讨论高血压的意愿，以及亚组参与者的WTP。 在1,023名随机参与者中，907人的回答符合质量指标并纳入最终样本。参与者平均年龄为63.6岁（标准差[SD]=9.6）；52.1%为女性。在所有组别中，愿意支付>$0的成年人比例均超过85%。各组中位每月自付WTP为20美元（四分位距10–50），不同框架间无显著差异（p=0.79），亚组中亦无差异。 结论：将抗高血压药物的益处框定为预防痴呆、CVD、死亡或其组合，并未影响患者对降压治疗的财务估值。 本文由 天纳乾坤 编辑 扫描二维码查看源文 Am J Prev Cardiol | Ahead of Print. 10.1016/j.ajpc.2026.102562 03 Trends Cardiovasc Med IF: 09.000 维生素D在肺动脉高压中的作用：从血管生物学到患者结局 Andrea Gulino, Sandra Ghelardoni, Letizia Mattii, Enza Polizzi, Anna Vittoria Mattioli, Rosalinda Madonna, etc. 肺动脉高压（PAH）是一种进行性肺血管疾病，以血管内皮功能障碍、过度血管收缩、血管重塑和右心室衰竭为特征。近年来，维生素D（VitD）被认为是PAH病理生物学中多个生物通路的潜在调节因子。除了在钙磷稳态中的经典作用外，VitD通过激活维生素D受体（VDR）发挥多效性作用，VDR表达于肺动脉内皮细胞和平滑肌细胞。 实验证据表明，VitD信号与PAH关键机制的调节相关，包括内皮一氧化氮产生、前列环素和内皮素通路、内皮-间质转化、平滑肌细胞增殖、炎症、氧化应激、线粒体功能障碍和细胞外基质重塑。在实验性肺动脉高压模型（包括具有PAH样血管重塑的模型）中，研究报道了VitD恢复与改善肺血流动力学、右心室功能、内皮功能和肺血管重塑之间的关联。然而，这些模型不能完全再现人类Group 1 PAH，因此其发现应谨慎解读。 临床研究显示，PAH患者中VitD缺乏的患病率很高，尽管一些研究纳入了异质性PH人群。较低的循环25-羟基维生素D水平与更差的功能分级、运动能力下降、更严重的血流动力学损害、右心室功能障碍和更差的生存率相关。然而，关于VitD补充获益的临床证据仍然有限，主要来自小型观察性研究和非对照干预。 这篇叙述性综述总结了当前将VitD与PAH病理生物学和患者结局联系起来的实验和临床证据，强调了潜在的机制通路，并讨论了未来治疗策略的机遇和挑战。尽管现有数据支持VitD/VDR信号与肺血管稳态之间生物学上合理的关联，但仍需要足够把握度的随机对照试验来确定纠正VitD缺乏是否与PAH临床结局改善相关。 本文由 天纳乾坤 编辑 扫描二维码查看源文 Trends Cardiovasc Med | Ahead of Print. 10.1016/j.tcm.2026.10.004 中国发表（14） China J R Soc Interface IF: 03.500Volume 23, Issue 243No.01Personalized haemodynamic modelling for non-invasive quantification of arterial stiffness in the human vasculature个性化血流动力学建模用于无创量化人体血管中的动脉僵硬度DOI: 10.1098/rsif.2025.1318 Molecular biomedicine IF: 10.100Volume 7, Issue 1No.02Mechanotransduction through oxidative stress upregulates circLyst to drive vascular remodeling in hypertensive humans and rodents机械转导通过氧化应激上调circLyst驱动高血压人类和啮齿动物的血管重塑DOI: 10.1186/s43556-026-00593-3 Annals of hematology IF: 02.400Volume 105, Issue 11No.03BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case reportBCMA CAR T细胞疗法治疗一例经重度预处理的复发/难治性POEMS综合征患者：病例报告DOI: 10.1007/s00277-026-07224-5 Zhongguo zhongyao zazhiVolume 51, Issue 17No.04[TCM pathogenesis of adverse reactions to molecularly targeted anti-tumor drugs in light of collateral disease theory]基于络病理论的分子靶向抗肿瘤药物不良反应的中医病机探讨DOI: 10.19540/j.cnki.cjcmm.20260514.502 J Psychosom Res IF: 03.300Volume 211, Issue No.05Cross-sectional independent associations of anxiety and depressive symptoms with cardiopulmonary exercise performance in treatment-naïve chronic thromboembolic pulmonary hypertension焦虑和抑郁症状与未治疗慢性血栓栓塞性肺动脉高压患者心肺运动表现的横断面独立关联DOI: 10.1016/j.jpsychores.2026.112993 Hypertension in Pregnancy IF: 02.100Volume 45, Issue 1, Page 2609374-2609374No.06Hypertensive disorders of pregnancy: epidemiology, pathophysiology, therapeutic strategies, and maternal-offspring outcomes妊娠期高血压疾病：流行病学、病理生理学、治疗策略及母胎结局DOI: 10.1080/10641955.2026.2742300 Ophthalmic epidemiology IF: 01.200Ahead of Print.No.07Association of Retinal Age Gap with Socioeconomic Deprivation: A Cross-Sectional Analysis of a Large Diverse Urban Cohort视网膜年龄差与社会经济剥夺的关联：一项大型多样化城市队列的横断面分析DOI: 10.1080/09286586.2026.2739999 Hypertension IF: 08.200Ahead of Print.No.08Aldosterone-Producing Lesions Harboring ATP1A1 and ATP2B3 Mutations: An International Multicenter Study携带ATP1A1和ATP2B3突变的醛固酮生成病变：一项国际多中心研究DOI: 10.1161/HYPERTENSIONAHA.126.27798 Int J Chron Obstruct Pulmon Dis IF: 03.100Volume 21, Issue No.09Association Between Cardiovascular Comorbidities and Clinical Outcomes in Patients Hospitalized for AECOPD心血管合并症与AECOPD住院患者临床结局的关联DOI: 10.2147/COPD.S641728 Journal of thoracic disease IF: 01.900Volume 18, Issue 9No.10Echocardiography-based multimodal models for thromboembolic risk prediction in atrial fibrillation: a narrative review基于超声心动图的多模态模型用于心房颤动血栓栓塞风险预测：叙述性综述DOI: 10.21037/jtd-2026-1700 FCVM IF: 02.900Volume 13, Issue No.11Predictive value of combined estimated plasma volume status and neutrophil-to-lymphocyte ratio for cardiovascular mortality in patients with acute myocardial infarction with heart failure联合估算血浆容量状态与中性粒细胞与淋巴细胞比值对急性心肌梗死合并心力衰竭患者心血管死亡率的预测价值DOI: 10.3389/fcvm.2026.1948520 FCVM IF: 02.900Volume 13, Issue No.12Evaluation of cardiovascular risk using smartwatch-measured pulse wave velocity in China: a nationwide cross-sectional study中国智能手表测量脉搏波速度评估心血管风险：一项全国性横断面研究DOI: 10.3389/fcvm.2026.1865667 Frontiers in public health IF: 03.400Volume 14, Issue No.13Parental obesity and offspring cardiometabolic trajectories from childhood to adulthood父母肥胖与子代从童年到成年的心血管代谢轨迹DOI: 10.3389/fpubh.2026.1836841 Chinese Medical Journal IF: 07.300Ahead of Print.No.14Chronic obstructive pulmonary disease increases the risk of cardiovascular disease occurrence in nonsmokers: A nationwide cohort study慢性阻塞性肺疾病增加非吸烟者心血管疾病发生风险：一项全国性队列研究DOI: 10.1097/CM9.0000000000004301 其他发布内容（35） More Published Articles Otolaryngol Clin North Am IF: 01.400Ahead of Print.No.01The Relationship among Obesity, Intracranial Hypertension, and Cerebrospinal Fluid Leak肥胖、颅内高压与脑脊液漏之间的关系DOI: 10.1016/j.otc.2026.07.001 Rev Peru Med Exp Salud Publica IF: 01.000Volume 43, Issue 3No.02Cerebral hemorrhage associated with snakebite by Bothrops spp. juvenile: experience of two cases in an amazonian referral hospital与幼年Bothrops属蛇咬伤相关的脑出血：亚马逊转诊医院的两例经验DOI: 10.17843/rpmesp.2026.433.15938 J Pediatr Hematol Oncol IF: 00.900Ahead of Print.No.03Body Composition Assessment and Correlation to Metabolic Profile in Survivors of Childhood Brain Tumors儿童脑肿瘤幸存者的身体成分评估及其与代谢特征的相关性DOI: 10.1097/MPH.0000000000003300 Advances in nutrition IF: 09.200Ahead of Print.No.04Dietary Patterns and Chronic Disease Risk: A Proteomic Framework to Strengthen Causal Inference膳食模式与慢性病风险：强化因果推断的蛋白质组学框架DOI: 10.1016/j.advnut.2026.100755 Cerebrovascular Diseases IF: 01.500Ahead of Print.No.05Bridging the Gap: Thrombolysis Access and Treatment Times Before and After Telestroke Implementation in Matão, Brazil弥合差距：巴西马唐市远程卒中实施前后溶栓可及性与治疗时间的变化DOI: 10.1159/ced/accag034 The Lancet Healthy Longevity IF: 14.600Ahead of Print.No.06Hearing loss, hearing-aid use, and mortality risk: individual participant data meta-analysis of population-based studies from Australia, Iceland, and the USA and a replication study from Norway听力损失、助听器使用与死亡风险：来自澳大利亚、冰岛和美国的基于人群研究的个体参与者数据荟萃分析及挪威的重复研究DOI: 10.1016/j.lanhl.2026.100903 Hypertension Research IF: 04.600Ahead of Print.No.07Hypertension detection, treatment and control in young adults in Australia澳大利亚年轻成人高血压的检测、治疗和控制DOI: 10.1038/s41440-026-02812-4 Hypertension IF: 08.200Ahead of Print.No.08Glycosylated Fibronectin Compared With sFlt-1/PlGF Ratio for Preeclampsia Assessment糖基化纤连蛋白与sFlt-1/PlGF比值在子痫前期评估中的比较DOI: 10.1161/HYPERTENSIONAHA.126.27232 J Hepatocell Carcinoma IF: 03.400Volume 13, Issue No.09Surgical Management of Hepatocellular Carcinoma Complicated by Severe Portal Hypertension Secondary to an Arterioportal Shunt: A Case Report继发于动门脉分流的严重门静脉高压并发症肝细胞癌的手术治疗：一例病例报告DOI: 10.2147/JHC.S642701 Annals of medicine and surgery IF: 01.600Volume 88, Issue 10No.10Therapeutic efficacy and safety of newly approved FDA drug levoketoconazole in cushing syndrome: a systematic review新获批FDA药物利拉鲁肽治疗库欣综合征的有效性和安全性：一项系统综述DOI: 10.1097/MS9.0000000000005471 Annals of medicine and surgery IF: 01.600Volume 88, Issue 10No.11Elevated lipoprotein(a) and adverse pregnancy outcomes脂蛋白(a)升高与不良妊娠结局DOI: 10.1097/MS9.0000000000005411 FCVM IF: 02.900Volume 13, Issue No.12Heart failure in Somalia: a scoping review of the epidemiology, etiology, clinical characteristics, management, outcomes, and evidence gaps索马里心力衰竭：流行病学、病因、临床特征、管理、结局及证据缺口范围综述DOI: 10.3389/fcvm.2026.1960696 Curēus IF: 01.300Volume 18, Issue 9No.13Association of the Triglyceride-Glucose Index with Systolic and Diastolic Blood Pressure Among Patients With Type 2 Diabetes Mellitus甘油三酯-葡萄糖指数与2型糖尿病患者收缩压和舒张压的关联DOI: 10.7759/cureus.117106 Int Med Case Rep J IF: 00.600Volume 19, Issue No.14Advanced Rheumatic Heart Disease Complicated by Pregnancy, Mitral Valve Disease, Pulmonary Hypertension, and Left Atrial Thrombus: A Multidisciplinary Case Report from Resource-Limited Settings晚期风湿性心脏病合并妊娠、二尖瓣病变、肺动脉高压及左心房血栓：来自资源有限地区的多学科病例报告DOI: 10.2147/IMCRJ.S643597 EJPC IF: 07.500Ahead of Print.No.15Temporal trends of heart failure epidemic in the Rotterdam Study over three decades鹿特丹研究三十年来心力衰竭流行的时间趋势DOI: 10.1093/eurjpc/zwag516 J Int Adv Otol IF: 01.200Volume 22, Issue 5No.16Ten-Year Experience with Combined Hyperbaric Oxygen and Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss: A Retrospective Cohort of 332 Patients联合高压氧与类固醇治疗特发性突发性感音神经性听力损失的十年经验：332例患者的回顾性队列研究DOI: 10.65717/iao.2026.252388 Annals of medicine and surgery IF: 01.600Volume 88, Issue 10No.17Determinants of hypertensive retinopathy among non-diabetic adults in comprehensive specialized hospitals of the Amhara region, northwest Ethiopia: a case-control study埃塞俄比亚西北部阿姆哈拉地区综合专科医院非糖尿病成人高血压视网膜病变的决定因素：病例对照研究DOI: 10.1097/MS9.0000000000005696 Annals of medicine and surgery IF: 01.600Volume 88, Issue 10No.18Left ventricular thrombus formation in paraganglioma: a rare but serious complication - a case report副神经节瘤中左心室血栓形成：一种罕见但严重的并发症——病例报告DOI: 10.1097/MS9.0000000000005621 Frontiers in medicine IF: 03.000Volume 13, Issue No.19Endoscopic resolution of esophageal varices in a patient with IgG4-related disease: a case reportIgG4相关疾病患者食管静脉曲张的内镜下消退：一例病例报告DOI: 10.3389/fmed.2026.1926636 MSMRVolume 33, Issue 9No.20Health outcomes of U.S. active component service members working in high risk occupations for blast overpressure exposure: a retrospective cohort study美国现役军人在爆炸超压暴露高风险职业中的健康结局：一项回顾性队列研究https://pubmed.ncbi.nlm.nih.gov/42865728 Journal of thoracic disease IF: 01.900Volume 18, Issue 9No.21Prognostic impact of surgical-side pulmonary artery diameter in patients with non-small cell lung cancer undergoing lobectomy手术侧肺动脉直径对接受肺叶切除术的非小细胞肺癌患者的预后影响DOI: 10.21037/jtd-2026-1627 FCVM IF: 02.900Volume 13, Issue No.22Perioperative temporary microaxial left ventricular assist device support in patients with low ejection fraction undergoing coronary artery bypass grafting低射血分数患者接受冠状动脉旁路移植术时的围术期临时微轴流泵左心室辅助装置支持DOI: 10.3389/fcvm.2026.1911213 Am J Lifestyle Med IF: 01.300Ahead of Print.No.23Applying Lifestyle Medicine to Improve Health Outcomes in People With Intellectual and Developmental Disabilities应用生活方式医学改善智力与发展性残疾人群的健康结局DOI: 10.1177/15598276261486805 Hypertension Research IF: 04.600Ahead of Print.No.24Association between the triglyceride-glucose index and arterial stiffness in adolescents: the Wakayama study青少年甘油三酯-葡萄糖指数与动脉僵硬度之间的关联：Wakayama研究DOI: 10.1038/s41440-026-02837-9 Hypertension Research IF: 04.600Ahead of Print.No.25Resting skin sympathetic nerve activity spectral characteristics are associated with orthostatic sympathetic responses and exaggerated orthostatic pressor response in hypertension静息皮肤交感神经活动频谱特征与高血压患者直立位交感反应及直立位升压反应增强相关DOI: 10.1038/s41440-026-02836-w Hypertension Research IF: 04.600Ahead of Print.No.26Association between caregiving duration and hypertension among family caregivers: the TMM CommCohort study家庭照护者照护时长与高血压之间的关联：TMM CommCohort研究DOI: 10.1038/s41440-026-02848-6 BMC ophthalmology IF: 01.700Volume 26, Issue 1No.27Systemic inflammation in optic neuropathies: comparative insights from hematological and composite indices视神经病变中的全身性炎症：血液学和复合指数的比较见解DOI: 10.1186/s12886-026-05433-0 Am J Hum Biol IF: 01.700Volume 38, Issue 10No.28Study Protocol for the Daasanach Human Biology Project: A Longitudinal Study of the Impact of Drinking Water Salinity and Heat Stress on Water Insecurity, Hydration, Energetics, Hypertension, and Kidney Function in Northern KenyaDaasanach人类生物学项目研究方案：饮用水盐度和热应激对肯尼亚北部水不安全、水合状态、能量代谢、高血压和肾功能影响的纵向研究DOI: 10.1002/ajhb.70343 Recent Adv Food Nutr AgricAhead of Print.No.29Medication-induced Micronutrient Deficiencies in Early-stage Chronic Kidney Disease早期慢性肾脏病中药物诱导的微量营养素缺乏DOI: 10.2174/012772574X431273251217105628 The AAPS journal IF: 03.700Volume 28, Issue 6No.30Physiologically based Biopharmaceutics Modeling (PBBM) Reveals a Low Dissolution-related Bioequivalence Risk for Immediate-Release Amlodipine Tablets基于生理的生物药剂学建模（PBBM）揭示速释氨氯地平片溶出相关的生物等效性风险较低DOI: 10.1208/s12248-026-01319-7 Population health management IF: 02.100Ahead of Print.No.31Community Paramedics Address Health Inequities Within EMS Through Mobile Integrated Healthcare (MIH) Program Referrals from a "Medical Home"社区急救人员通过从“医疗之家”转诊至移动整合医疗（MIH）项目来解决EMS内的健康不平等问题DOI: 10.1177/19427891261496776 Aesthetic plastic surgery IF: 02.800Ahead of Print.No.32Advanced Age is Not Associated With An Increased Risk of Postoperative Complications in Breast Reduction Surgery: A Comparative Study on 1716 Patients高龄与乳房缩小术后并发症风险增加无关：一项1716例患者的比较研究DOI: 10.1007/s00266-026-06367-0 Pediatrics international IF: 00.900Volume 68, Issue 1No.33A Case of Pulmonary Hypertensive Crisis Following Treatment of Retinopathy of Prematurity in an Extremely Preterm Infant一例极早产儿早产儿视网膜病变治疗后发生肺动脉高压危象的病例DOI: 10.1111/ped.70558 Nutrition and health IF: 01.400Ahead of Print.No.34Linking obesity and type 2 diabetes: Mechanistic insights and personalized nutritional strategies肥胖与2型糖尿病的关联：机制见解与个性化营养策略DOI: 10.1177/02601060261496967 Curr Opin Nephrol Hypertens IF: 02.400Volume 35, Issue 6No.35Beyond creatinine: biomarkers of kidney recovery after acute kidney injury超越肌酐：急性肾损伤后肾脏恢复的生物标志物DOI: 10.1097/MNH.0000000000001218 46 Hypertension(HTN) 高血压 3 ANTIHYPERTENSIVES 抗高血压药 1 Essential Hypertension 原发性高血压 1 Hypertensive Crisis 高血压危象 编辑：天纳乾坤 审校：赵婷